FIELD: medicine.
SUBSTANCE: invention relates to the use of a compound of formula (I), as well as its acid salts, as a neuroprotective agent in the prevention of a neurodegenerative disease selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and neurodegenerative disease caused by ischemia or traumatic brain injury. In the general formula (I), X represents a halogen atom (Hal), where (Hal) represents fluorine, chlorine, bromine or iodine; Y represents an oxygen atom; m, n, r and s have the value 1; R is a straight or branched C1-C5 alkyl group; R' is C3-C10 cycloalkyl.
EFFECT: obtaining an agent for the treatment of neurodegerative diseases.
10 cl, 18 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TUBULIN CARBOXYPEPTIDASES (TCP) | 2018 |
|
RU2797200C1 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASES ASSOCIATED WITH TUBULIN CARBOXYPEPTIDASES (TCP) | 2018 |
|
RU2812207C2 |
| USE OF A CYCLIC TRIPEPTIDE TO IMPROVE CELLULAR ENERGY METABOLISM | 2016 |
|
RU2737116C2 |
| INTEGRATED HUMAN PLATELET LYSATE, A METHOD OF PRODUCING INTEGRATED HUMAN PLATELET LYSATE AND THE USE OF INTEGRATED HUMAN PLATELET LYSATE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | 2018 |
|
RU2802440C2 |
| 3β-(Benzyloxy)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | 2019 |
|
RU2796005C2 |
| 3-β(4-METHOXYBENZYLOXY)PREGN-5-EN-20-ONE FOR USE IN TREATMENT OF DISORDERS RELATED TO CONSUMPTION OF CANNABINOIDS | 2019 |
|
RU2788004C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN 1 FOR PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | 2016 |
|
RU2770021C2 |
| ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
| PHARMACOLOGICAL NEUROPROTECTIVE DRUG | 2014 |
|
RU2561045C1 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
